

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOCARE

诺诚健华

InnoCare Pharma Limited

諾誠健華醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9969)

**(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR
AND
(2) CHANGE IN COMPOSITION OF BOARD COMMITTEES**

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of InnoCare Pharma Limited (the “**Company**”) hereby announces that Dr. Zemin Jason Zhang (“**Dr. Zhang**”) has tendered his resignation as an independent non-executive Director, a member of the Audit Committee, a member of the Compensation Committee and a member of the Nomination Committee of the Company with effect from 14 July 2023 as he needed more time for his dedication in academic research as a tenured professor at the School of Life Sciences of Peking University.

Dr. Zhang has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation from the position that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company. The Board would like to take this opportunity to thank Dr. Zhang for his contributions to the Company during his tenure of office as an independent non-executive Director.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board also announces that subsequent to, and concurrent with the resignation of Dr. Zhang as a member of each of the Compensation Committee, the Nomination Committee and the Audit Committee:

- (i) Dr. Kaixian Chen, an independent non-executive Director, has been appointed as a member of the Compensation Committee;
- (ii) Ms. Lan Hu, an independent non-executive Director, has been appointed as a member of the Nomination Committee; and
- (iii) Mr. Ronggang Xie, a non-executive Director, has been appointed as a member of the Audit Committee.

The Board would like to take this opportunity to welcome Dr. Kaixian Chen, Ms. Lan Hu and Mr. Ronggang Xie on their new appointment.

Following the resignation of Dr. Zhang, the Company has two independent non-executive Directors, which results in the current number of independent non-executive Directors falling below the minimum number required under Rule 3.10(1) of the Listing Rules.

The Company will use its best endeavour to identify suitable candidate to fill up the vacancy of independent non-executive Director in any event within three months from the date of resignation of Dr. Zhang as required under Rules 3.11 of the Listing Rules. The Company will make further announcement(s) as and when appropriate.

By Order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and Executive Director

Hong Kong, 14 July 2023

As at the date of this announcement, the Board of Directors comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi, Mr. Ronggang Xie and Mr. Ming Jin as non-executive Directors, and Ms. Lan Hu and Dr. Kaixian Chen as independent non-executive Directors.